Clinical Trials on Growth in Japan

Total 26 results

Pfizer

Recruiting

Ngenla Subcutaneous Injection Special Investigation

Growth Hormone Deficiency Without Epiphyseal Closure

Japan
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Versartis Inc.

Terminated

Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)

Growth Disorders | Pediatric Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Completed

Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

Foetal Growth Problem | Small for Gestational Age

Japan
Novo Nordisk A/S

Recruiting

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Growth Hormone Deficiency in Children

Japan
Novo Nordisk A/S

Completed

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome (NordiPAD)

Turner Syndrome | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Genetic Disorder

Japan
Novo Nordisk A/S

Completed

Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Foetal Growth Problem | Small for Gestational Age

Japan
Novo Nordisk A/S

Completed

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

Adult Growth Hormone Deficiency

Japan
Eli Lilly and Company

Completed

Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency

Adult Growth Hormone Deficiency

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Novo Nordisk A/S

Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency (REAL 2)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

Denmark, France, Germany, Japan, Sweden, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

Urothelial Cancer | Receptors, Fibroblast Growth Factor

United States, Italy, Belgium, United Kingdom, Japan, Turkey, Brazil, Ukraine, Spain, Russian Federation, Israel, France, Germany, Argentina
Novo Nordisk A/S

Recruiting

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

United States, Japan, Israel, India, Austria, Slovenia, Belgium, Brazil, France, Germany, Sweden, Turkey, Ukraine
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Ascendis Pharma Endocrinology Division A/S

Active, not recruiting

A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency

Endocrine System Diseases | Adult Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Greece, Ukraine, Australia, Canada, France, Israel, Italy, Japan, Malaysia, Poland, Romania, Serbia, Slovakia, Spain, Turkey, United Kingdom, Germany, Korea, Republic of
Novo Nordisk A/S

Active, not recruiting

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4) (REAL4)

Growth Hormone Deficiency in Children

United States, Korea, Republic of, United Kingdom, Canada, Russian Federation, India, Spain, Italy, Algeria, Austria, France, Ireland, Israel, Japan, Latvia, Poland, Serbia, Thailand, Ukraine, Germany, Slovenia, Switzerland
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
OPKO Health, Inc.

Completed

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Growth Hormone Deficiency

Japan
Ascendis Pharma Endocrinology Division A/S

Completed

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)

Endocrine System Diseases | Growth Hormone Deficiency | Hormone Deficiency

United States, Armenia, Georgia, Turkey, Ukraine, Australia, Canada, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico

Clinical Trials on Growth in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations